The global Psoriatic Arthritis Treatment Market was valued at USD 11.08 billion in 2023, projected to reach USD 25.41 billion by 2032 with a CAGR of 9.70%. Growth is driven by rising disease prevalence, advancements in therapies, favorable reimbursement, and increasing healthcare spending, particularly in developing regions.

In the U.S., the market reached USD 3.33 billion in 2023, expected to hit USD 7.36 billion by 2032. North America leads the market due to advanced healthcare facilities, high biologic adoption, and favorable reimbursement policies, supporting its regional dominance.

Biologics hold a 31.54% market share in the psoriatic arthritis treatment market in 2023, favored for their efficacy, targeted action, and reduced adverse effects. Injectable biologics dominate the market with a 42.13% share, offering fast relief for moderate-to-severe conditions and improved patient adherence.

Hospital pharmacies lead the psoriatic arthritis treatment market due to high biologics demand, requiring close medical monitoring. North America dominates the market with a 39.46% share in 2023, driven by robust healthcare facilities, strong awareness, and broad reimbursement coverage.

Asia Pacific is expected to register the fastest growth in the psoriatic arthritis treatment market due to increasing patient population, developing healthcare infrastructure, and improved access to specialty medication. Key players in the market include AbbVie, Amgen, Johnson & Johnson, Novartis, and more, offering a range of treatment options.

The market report provides detailed segmentation by drug class, route of administration, and distribution channel. Market size is projected to reach USD 25.41 billion by 2032 with a CAGR of 9.70%, driven by rising incidence of psoriatic arthritis, access to biologic therapies, favorable reimbursement frameworks, and clinical R&D advancements.

Read more at GlobeNewswire: Psoriatic Arthritis Treatment Market Set to Surpass USD